Back to top
more

Aurinia Pharmaceuticals Inc (AUPH)

(Delayed Data from NSDQ)

$11.35 USD

11.35
2,767,908

-0.22 (-1.90%)

Updated Jul 23, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 11% (224 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

New Strong Sell Stocks for July 15th

ATEC, DRNA, AG, PAX, and AUPH have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2021

Is the Options Market Predicting a Spike in Aurinia (AUPH) Stock?

Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Misses Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -14.29% and -60.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Aurinia (AUPH) This Earnings Season?

Aurinia (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?

On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.

Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).

Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis

Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Aurinia (AUPH) Looks Good: Stock Adds 5.5% in Session

Aurinia (AUPH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Should You Buy Aurinia Pharmaceuticals (AUPH) Ahead of Earnings?

Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -27.27% and -50.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More

Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.

Aerie to Initiate Phase IIb Study for Dry Eye Treatment

The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.

Aurinia Completes Final Patient Treatment in Dry Eye Study

Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -13.04% and -53.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH

Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.

Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Misses Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 25.00% and -50.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?

Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.